New drug tested for rare kidney disease halted early
NCT ID NCT04652570
Summary
This early-stage study tested a new drug called VB119 for adults with primary membranous nephropathy, a kidney disease that causes harmful protein loss in urine. The main goal was to find a safe dose and see how the body processes the drug. The study was terminated early and only enrolled 6 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Albany, New York, 12209, United States
-
Clinical Research Site
Bethlehem, Pennsylvania, 18017, United States
-
Clinical Research Site
Dallas, Texas, 75208, United States
-
Clinical Reserach Site
Los Angeles, California, 91324, United States
Conditions
Explore the condition pages connected to this study.